The Reserve Bank of Australia is still lagging its American counterpart, with no indication it is close to beginning its rate ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

GSK has received Canadian approval for its respiratory syncytial virus vaccine in adults between 50 and 59, the company said ...

Respiratory illnesses like the flu and COVID-19 spread more commonly in the fall and winter months ahead, and doctors in ...

The respiratory virus is the leading cause of hospitalisation for infants, with 12,000 babies admitted each year. Before next ...

The federal government will spend more than $174 million to give pregnant women a free vaccine for RSV ahead of next year’s ...

Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...

The federal government will place RSV vaccines on the national immunisation program, as 12,000 babies are hospitalised with ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Moderna says Health Canada has approved its mRNA vaccine to protect against respiratory syncytial virus in adults age 60 and ...

RSV vaccination for infants and mothers should be administered either in the hospital or directly from a primary health-care ...